Steward Partners Investment Advisory’s Maravai LifeSciences MRVI Stock Holding History

Steward Partners Investment Advisory’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20	Closed	-$109	–	4106
2024 Q4	$109	Hold	20	–	–	﹤0.01%	3918
2024 Q3	$166	Hold	20	–	–	﹤0.01%	3655
2024 Q2	$143	Hold	20	–	–	﹤0.01%	3542
2024 Q1	$173	Hold	20	–	–	﹤0.01%	3478
2023 Q4	$131	Hold	20	–	–	﹤0.01%	3432
2023 Q3	$200	Hold	20	–	–	﹤0.01%	3292
2023 Q2	$249	Hold	20	–	–	﹤0.01%	3228
2023 Q1	$280	Hold	20	–	–	﹤0.01%	3211
2022 Q4	$286	Sell	20 -98	-83%	-$1.54K	﹤0.01%	3234
2022 Q3	$3K	Sell	118 -1,236	-91%	-$31K	﹤0.01%	2953
2022 Q2	$38K	Buy	1,354 +1,334	+6,670%	+$42.3K	﹤0.01%	1936
2022 Q1	$1K	Hold	20	–	–	﹤0.01%	3199
2021 Q4	$1K	Hold	20	–	–	﹤0.01%	3102
2021 Q3	$1K	Buy	+20	New	+$976	﹤0.01%	3088

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Steward Partners Investment Advisory's MRVI Position: Q1 2025 in Review

Steward Partners Investment Advisory sold out of Maravai LifeSciences (MRVI) in Q1 2025, closing a stake of 20 shares — an estimated $109 sold.

Steward Partners Investment Advisory first reported a position in MRVI in Q3 2021 and held it in 14 quarters. The position peaked at $38K in Q2 2022. 184 funds tracked by Wall St. Rank hold MRVI as of Q1 2025.

Steward Partners Investment Advisory reported no remaining Maravai LifeSciences position as of Q1 2025 after selling out during the quarter.
Steward Partners Investment Advisory sold 20 Maravai LifeSciences shares in Q1 2025, an estimated $109.
Steward Partners Investment Advisory first reported a position in Maravai LifeSciences in Q3 2021 and held it in 14 quarters.
Steward Partners Investment Advisory's Maravai LifeSciences position peaked at $38K in Q2 2022.
184 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2025.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2025, filed 13 May 2025.